Tag: Xaluritamig

Xaluritamig (AMG 509) is an investigational immunotherapy showing encouraging antitumor activity in patients with heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) [1.2.1, 1.6.9]. A key aspect of its clinical profile is its pharmacokinetics, so **what is the half life of Xaluritamig?**

According to preliminary pharmacokinetic data from a Phase 1 study, the investigational T-cell engager AMG 509 (xaluritamig) has a mean terminal half-life of approximately 3 to 4 days. This specific pharmacokinetic profile is a key aspect of understanding the drug’s behavior and dosing schedule in clinical development.

In a Phase 1 study of 97 patients with metastatic castration-resistant prostate cancer, 49% experienced a significant drop in prostate-specific antigen levels after treatment with xaluritamig [1.2.3]. So, **what is amg 509** and how does this promising immunotherapy work?

In a clinical study published in *Cancer Discovery*, 49% of heavily pretreated patients with metastatic castration-resistant prostate cancer experienced a significant reduction in prostate-specific antigen (PSA) levels with the experimental immunotherapy Xaluritamig. This article explores this promising new treatment strategy and its role in oncology.